End the Vaccine Carveout Act

What happened: Senator Rand Paul (R-KY) introduced S.3853 on February 11, 2026. It was read twice and referred to the Committee on Health, Education, Labor, and Pensions. The bill would amend the Public Health Service Act to allow civil lawsuits against vaccine manufacturers without first filing through the National Vaccine Injury Compensation Program, effectively ending the liability shield provided by the PREP Act. Status: Early stage, referred to committee, one cosponsor (Sen. Lee). No hearings, no markup, no floor action. The companion bill H.R. 4668 was referred to House Energy and Commerce — same status. Passage probability is near zero in the current Congress given the sponsor's limited cross-party support.

Money trail: There is zero funding authorized or appropriated. This bill does not create a spending program, tax credit, or procurement vehicle. The only economic mechanism is a change in liability regime — shifting risk from the federal VICP program to vaccine manufacturers' balance sheets. For pure-play vaccine companies, that increased legal risk would raise operating costs (insurance, legal reserves) and potentially reduce willingness to produce vaccines for U.S. markets under government contracts. For diversified pharma with vaccine lines as a small fraction of revenue (Pfizer, Merck, Johnson & Johnson), the impact is marginal because their legal costs are already spread across larger revenue bases and diversified product portfolios.

Structural winners and losers: Pure-play vaccine manufacturers are the clear structural losers. Moderna ($MRNA, current $47.39) generates essentially all revenue from its COVID-19 franchise (Spikevax). Novavax ($NVAX, current $8.17) has one approved product. Diversified players — Pfizer ($PFE, $26.73), Merck ($MRK, $111.04), Johnson & Johnson ($JNJ, $230.47) — have vaccine revenue as a small portion of total sales (Pfizer's Comirnaty revenue ~5% of total, JNJ's vaccine segment even smaller). The liability change would produce a proportionate cost increase, not a structural business model threat.

Real market data: As of April 30, 2026, $MRNA is at $47.39, down 6.6% over 7 days and 6.73% over 30 days, trading below the midpoint of its 52-week range ($22.28–$59.55). $NVAX is at $8.17, down 0.61% over 7 days but essentially flat (+0.37%) over 30 days. Neither stock shows any discernible reaction to this bill — the February 11 introduction date produced no price dislocation around that period. The market has correctly priced in that a bill with one cosponsor and zero committee actions has negligible passage odds.

Timeline: No scheduled hearings or markups. The 119th Congress runs through January 2027. For this bill to become law, it would need: (1) committee markup and passage, (2) floor vote in the Senate, (3) identical companion bill passage in the House, (4) conference committee, (5) presidential signature. None of those steps are imminent or likely given the legislative calendar and current partisan dynamics.